Wall Street Zen upgraded shares of HUTCHMED (NASDAQ:HCM - Free Report) from a buy rating to a strong-buy rating in a research note released on Friday morning.
Separately, HSBC downgraded shares of HUTCHMED from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th.
Get Our Latest Stock Analysis on HCM
HUTCHMED Trading Up 4.0%
Shares of HCM stock traded up $0.61 during trading hours on Friday, hitting $15.96. 208,142 shares of the company's stock traded hands, compared to its average volume of 101,194. The stock's 50 day simple moving average is $14.05 and its 200 day simple moving average is $14.75. HUTCHMED has a 12 month low of $11.51 and a 12 month high of $21.50. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. Barclays PLC raised its position in shares of HUTCHMED by 1,483.6% in the 4th quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after acquiring an additional 2,255 shares in the last quarter. Public Employees Retirement System of Ohio increased its stake in HUTCHMED by 49.6% in the fourth quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock valued at $39,000 after purchasing an additional 899 shares in the last quarter. Blue Trust Inc. increased its stake in HUTCHMED by 99.9% in the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock valued at $102,000 after purchasing an additional 3,532 shares in the last quarter. Summit Trail Advisors LLC increased its stake in HUTCHMED by 14.4% in the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock valued at $189,000 after purchasing an additional 1,647 shares in the last quarter. Finally, OLD Mission Capital LLC bought a new stake in HUTCHMED in the fourth quarter valued at $230,000. 8.82% of the stock is owned by institutional investors.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Articles
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
